XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Xcede Technologies, Inc. Joint Venture (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Nov. 30, 2016
Dec. 31, 2018
Cook Biotech Inc [Member]    
Line of Credit Facility, Maximum Borrowing Capacity   $ 1.5
Long-term Line of Credit   $ 0.5
Noncontrolling Interest [Member]    
Debt Conversion, Original Debt, Amount $ 3.1  
Debt Conversion, Converted Instrument, Shares Issued 3,100,000  
Xcede Technologies inc [Member]    
Debt Instrument, Interest Rate, Stated Percentage 5.00%  
Committed Investment In Cash $ 1.2  
Debt Conversion, Converted Instrument, Shares Issued 3,055,551  
Capital Stock Financing Discount Percentage 20.00%  
Noncontrolling Interest, Description   Noncontrolling interest represents the value of the Series A Preferred and common stock not owned by DBM plus 17% of cumulative losses of Xcede based on the 17% common stock ownership held by noncontrolling interests.
Equity Method Investment, Ownership Percentage   63.00%
Dynasil Biomedical [Member]    
Debt Conversion, Original Debt, Amount $ 2.4  
Debt Conversion, Converted Instrument, Shares Issued 2,338,569  
External Funding [Member] | Convertible Debt [Member]    
Debt Conversion, Original Debt, Amount $ 5.2  
Series B Preferred Stock [Member]    
Preferred Stock, Liquidation Preference Per Share   $ 1.27
Preferred Stock, Liquidation Preference, Value   $ 1.5
Series A Preferred Stock [Member]    
Preferred Stock, Liquidation Preference Per Share   $ 1.016
Preferred Stock, Liquidation Preference, Value   $ 5.5
Series A Preferred Stock [Member] | Dynasil Biomedical [Member]    
Preferred Stock, Liquidation Preference, Value   $ 2.4